Kinnevik Investment


Upgrading our NAV; Babylon goes the SPAC route

03/06/21 -"We updated our estimated DCF following the announcement of Babylon Health's definitive merger agreement with the SPAC Alkuri Global, through which the London-based digital healthcare company will ..."

Pages
61
Language
English
Published on
03/06/21
You may also be interested by these reports :
18/03/26
Bolloré completed a calm 2025 year but announced a surprising €4.2bn exceptional dividend. However, Compagnie de l’Odet will redistribute 2/3 of that ...

17/03/26

16/03/26
We have revised downwards our estimates for 2025 on the net income provided by Eurazeo (the only element of the income statement provided in the ...

16/03/26
Our change in recommendation from Add to Buy mainly stems from the significant increase in the 2025 dividend, of 25% to €2 per share, when we had ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO